MMRGlobal Receives Significant Intellectual Property Milestone Payment
LOS ANGELES, CA--(Marketwired - Sep 17, 2014) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR" or the "Company") today announced that it has received another significant milestone payment pursuant to an existing Non-Exclusive License Agreement (the "Agreement") pertaining to the Company's biotech assets. Additional information regarding this milestone payment will be contained in the Company's quarterly report on Form 10-Q for the quarter ending September 30, 2014. The non-exclusive Agreement licenses the use of the Company's clinical and scientific data relating to targeted immunotherapies for cancer and other disease treatments to stimulate a patient's immune response and certain other confidential information.
MMRGlobal's licensed assets are part of the Company's worldwide intellectual property rights to numerous biotech assets including international patents, vaccine and patient samples and anti-CD20 monoclonal antibodies.
Although MMR's primary focus is as a provider and licensor of health IT products and services, it has a growing list of patents and other intellectual property related to cancer-fighting anti-CD20 monoclonal antibodies under the title, "Antibodies and Methods For Making and Using Them," issued in the U.S., Mexico, Australia and South Korea with patents pending in the U.S., Australia, Brazil, Canada, China, Hong Kong, India, Europe, Japan and Korea. The Company also holds additional patents pertaining to its B-cell idiotype vaccine worldwide.
Additionally, through its wholly owned subsidiary, MyMedicalRecords, Inc., the Company has a health IT patent portfolio consisting of 13 issued U.S. patents, 17 pending U.S. applications, and numerous issued patents and pending applications in other countries or regional authorities of commercial interest including Australia, Singapore, New Zealand, Mexico, Japan, Canada, China, Hong Kong, South Korea, Israel and Europe. The Company's primary business is selling and licensing Personal Health Records products and services and other patented health information technologies to physicians, hospitals and other healthcare providers and also retailers, employers and professional organizations.